#NASH

Duke Researchers ID New Target for Fatty Liver Disease Treatment

Advocates at the Global Liver Institute are declaring the liver disease a “hidden epidemic” across the globe.

International NASH Day is June 12. This day is set aside to raise awareness of the fatty liver disease, NASH

A placebo-controlled study of obeticholic acid showed it improved liver fibrosis with no worsening of non-alcoholic steatohepatitis.

If you live with liver disease, you need knowledge about how your liver works, so you can give it lots of support, and live longer...

The herbicide has been making headlines over allegations it could be linked to cancer—but scientists say there are other risks too.

A quick overview of Hep Magazine’s reporting on the 53rd International Liver Congress in Vienna

Selonsertib did not improve liver fibrosis more than a placebo.

Recent research shows about 1 in 4 people in the United States have fatty liver disease. Among Latinos, the rate is significantly higher.

Among HIV-positive people, mortality related to hepatitis B and C is falling but deaths due to NAFLD are rising.

At the 24-week mark of a 48-week trial, the treatment showed a trend toward a lack of efficacy.

Nearly a quarter of those taking a higher dose of Ocaliva saw an improvement in liver scarring.

Non-alcoholic fatty liver disease is caused by excess fat in the liver, and can worsen into non-alcoholic steatohepatitis (NASH).

A placebo-controlled study of obeticholic acid showed it improved liver fibrosis with no worsening of non-alcoholic steatohepatitis.